Last reviewed · How we verify
Dabigatran and Apixaban
Dabigatran and apixaban are direct oral anticoagulants that inhibit blood clotting factors to prevent thromboembolism.
Dabigatran and apixaban are direct oral anticoagulants that inhibit blood clotting factors to prevent thromboembolism. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention.
At a glance
| Generic name | Dabigatran and Apixaban |
|---|---|
| Also known as | Pradaxa and Eliquis |
| Sponsor | University of Sao Paulo General Hospital |
| Drug class | Direct oral anticoagulant (DOAC) |
| Target | Dabigatran: Factor IIa (thrombin); Apixaban: Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Dabigatran is a direct thrombin inhibitor that blocks Factor IIa, while apixaban is a Factor Xa inhibitor; both prevent the formation of blood clots by interrupting the coagulation cascade. This Phase 3 study likely compares the efficacy and safety of these two anticoagulants in a specific clinical population, such as patients with atrial fibrillation or venous thromboembolism.
Approved indications
- Atrial fibrillation for stroke prevention
- Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention
Common side effects
- Bleeding (major and minor)
- Dyspepsia
- Gastrointestinal bleeding
- Intracranial hemorrhage
Key clinical trials
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants) (NA)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia (PHASE4)
- Anticoagulation in Patients With Venous Thromboembolism and Cancer
- High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
- A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects (PHASE1)
- SNAP AF-52: Dose Appropriateness and Adherence to Oral Anticoagulation in Adults ≥65 With Atrial Fibrillation in Primary Care (Ordu, Türkiye)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |